DuraLock-C Catheter Lock Solution

TerminatedOBSERVATIONAL
Enrollment

17

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

June 1, 2023

Study Completion Date

June 1, 2023

Conditions
Catheter-Related InfectionsCitrate Adverse Reaction
Interventions
DEVICE

Locking Solution

The total duration of the study treatment period will be 90 calendar days, from Visit 1 Pre-Instillation to the last study-related assessment. Two to 3 instillations (1 per lumen per visit) of DuraLock-C 4.0%, 30.0%, or 46.7% (equivalent to the catheter manufacturer's prescribed priming volume) will be instilled 1 to 3 days apart (with a HD schedule of 3 to 4 times per week); each instillation of CLS will remain in the CVC for approximately 24 to 72 hours ± 12 hours, based on their practice preferences. EOS will take place at the patient's next scheduled dialysis session.

Trial Locations (1)

Unknown

Clinique HEMERA Pays de Caux, 14 .A avenue Foch, Yvetot

Sponsors
All Listed Sponsors
collaborator

Syneos Health

OTHER

collaborator

Veeva Systems

INDUSTRY

lead

Medical Components, Inc dba MedComp

INDUSTRY